Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Bioorg Med Chem Lett ; 30(17): 127374, 2020 09 01.
Article in English | MEDLINE | ID: mdl-32738983

ABSTRACT

A series of O-substituted analogues of the B,C-ring truncated scaffold of deguelin were designed as C-terminal inhibitors of heat shock protein 90 (HSP90) and investigated as novel antiproliferative agents against HER2-positive breast cancer. Among the synthesized compounds, compound 80 exhibited significant inhibition in both trastuzumab-sensitive and trastuzumab-resistant breast cancer cells, whereas compound 80 did not show any cytotoxicity in normal cells. Compound 80 markedly downregulated the expression of the major client proteins of HSP90 in both cell types, indicating that the cytotoxicity of 80 in breast cancer cells is attributed to the destabilization and inactivation of HSP90 client proteins and that HSP90 inhibition represents a promising strategy to overcome trastuzumab resistance. A molecular docking study of 80 with the homology model of a HSP90 homodimer showed that 80 fit nicely in the C-terminal domain with a higher electrostatic complementary score than that of ATP.


Subject(s)
Antineoplastic Agents/chemistry , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Rotenone/analogs & derivatives , Antineoplastic Agents/metabolism , Antineoplastic Agents/pharmacology , Binding Sites , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Line, Tumor , Cell Survival/drug effects , Down-Regulation/drug effects , Drug Evaluation, Preclinical , Drug Resistance, Neoplasm/drug effects , Female , HSP90 Heat-Shock Proteins/metabolism , Humans , Molecular Docking Simulation , Rotenone/chemistry , Rotenone/metabolism , Rotenone/pharmacology , Structure-Activity Relationship
2.
Bioorg Med Chem Lett ; 30(3): 126838, 2020 02 01.
Article in English | MEDLINE | ID: mdl-31864799

ABSTRACT

A series of indane-type acetamide and propanamide analogues were investigated as TRPV1 antagonists. The analysis of structure-activity relationship indicated that indane A-region analogues exhibited better antagonism than did the corresponding 2,3-dihydrobenzofuran and 1,3-benzodioxole surrogates. Among them, antagonist 36 exhibited potent and selective antagonism toward capsaicin for hTRPV1 and mTRPV1. Further, in vivo studies indicated that antagonist 36 showed excellent analgesic activity in both phases of the formalin mouse pain model and inhibited the pain behavior completely at a dose of 1 mg/kg in the 2nd phase.


Subject(s)
Amides/chemistry , Indans/chemistry , TRPV Cation Channels/antagonists & inhibitors , Acetamides/chemistry , Acetamides/metabolism , Acetamides/therapeutic use , Amides/metabolism , Amides/therapeutic use , Analgesics/chemistry , Analgesics/therapeutic use , Animals , Capsaicin/chemistry , Capsaicin/metabolism , Drug Design , Drug Evaluation, Preclinical , Humans , Mice , Pain/chemically induced , Pain/drug therapy , Pyridines/chemistry , Structure-Activity Relationship , TRPV Cation Channels/metabolism
3.
J Med Chem ; 63(1): 418-424, 2020 01 09.
Article in English | MEDLINE | ID: mdl-31702924

ABSTRACT

Paradoxically, some TRPV1 agonists are, at the organismal level, both nonpungent and clinically useful as topical analgesics. Here, we describe the scaled-up synthesis and characterization in mouse models of a novel, nonpungent vanilloid. Potent analgesic activity was observed in models of neuropathic pain, and the compound blocked capsaicin induced allodynia, showing dermal accumulation with little transdermal absorption. Finally, it displayed much weaker systemic toxicity compared to capsaicin and was negative in assays of genotoxicity.


Subject(s)
Analgesics/therapeutic use , Phenylurea Compounds/therapeutic use , TRPV Cation Channels/agonists , Thiazoles/therapeutic use , Analgesics/chemical synthesis , Analgesics/pharmacokinetics , Analgesics/toxicity , Animals , CHO Cells , Capsaicin , Cricetulus , Drug Discovery , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Mice, Inbred ICR , Neuralgia/drug therapy , Phenylurea Compounds/chemical synthesis , Phenylurea Compounds/pharmacokinetics , Phenylurea Compounds/toxicity , Swine , Thiazoles/chemical synthesis , Thiazoles/pharmacokinetics , Thiazoles/toxicity
4.
Sci Rep ; 8(1): 6409, 2018 04 23.
Article in English | MEDLINE | ID: mdl-29686295

ABSTRACT

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is latent but constitutively activated in many types of cancers. It is well known that STAT3 plays a key role in inflammation-associated tumorigenesis. Curcumin is an anti-inflammatory natural compound isolated from the turmeric (Curcuma longa L., Zingiberaceae) that has been extensively used in a traditional medicine over the centuries. In the present study, we have found that curcumin inhibits STAT3 signaling that is persistently overactivated in H-Ras transformed breast epithelial cells (H-Ras MCF10A). Specific cysteine residues present in STAT3 appear to be critical for the activity as well as conformation of this transcription factor. We identified the cysteine residue 259 of STAT3 as a putative site for curcumin binding. Site-directed mutation of this cysteine residue abolished curcumin-induced inactivation of STAT3 and apoptosis in H-Ras MCF10A cells. The α,ß-unsaturated carbonyl moiety of curcumin appears to be essential in its binding to STAT3 in H-Ras MCF10A cells. Tetrahydrocurcumin that lacks such electrophilic moiety failed to interact with STAT3 and to induce apoptosis in the same cell line. Taken together, our findings suggest that curcumin can abrogate aberrant activation of STAT3 through direct interaction, thereby inhibiting STAT3-mediated mammary carcinogenesis.


Subject(s)
Apoptosis/drug effects , Curcumin/metabolism , Curcumin/pharmacology , Cysteine/metabolism , Genes, ras , Mammary Glands, Human/drug effects , STAT3 Transcription Factor/metabolism , Cell Line, Transformed , Curcumin/analogs & derivatives , DNA/metabolism , Dimerization , Humans , Mammary Glands, Human/pathology , STAT3 Transcription Factor/chemistry , Sulfhydryl Compounds/metabolism , Transcription, Genetic
5.
J Cancer Prev ; 23(1): 18-24, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29629345

ABSTRACT

BACKGROUND: Curcumin, a yellow ingredient of turmeric (Curcuma longa Linn, Zingiberaceae), has long been used in traditional folk medicine in the management of inflammatory disorders. Although curcumin has been reported to inhibit experimentally-induced colitis and carcinogenesis, the underlying molecular mechanisms remain largely unresolved. METHODS: Murine colitis was induced by dextran sulfate sodium (DSS) which mimics inflammatory bowel disease. Curcumin or tetrahydrocurcumin was given orally (0.1 or 0.25 mmol/kg body weight daily) for 7 days before and together with DSS administration (3% in tap water). Collected colon tissue was used for histologic and biochemical analyses. RESULTS: Administration of curcumin significantly attenuated the severity of DSS-induced colitis and the activation of NF-κB and STAT3 as well as expression of COX-2 and inducible nitric oxide synthase. In contrast to curcumin, its non-electrophilic analogue, tetrahydrocurcumin has much weaker inhibitory effects. CONCLUSIONS: Intragastric administration of curcumin inhibited the experimentally induced murine colitis, which was associated with inhibition of pro-inflammatory signaling mediated by NF-κB and STAT3.

6.
Bioorg Med Chem ; 12(21): 5505-13, 2004 Nov 01.
Article in English | MEDLINE | ID: mdl-15465327

ABSTRACT

Seven fluorine-substituted 1H-pyrrolo[2,3-b]pyridine derivatives were synthesized based on a lead ligand, 3-[[4-(4-iodophenyl)piperazin-1-yl]-methyl]-1H-pyrrolo[2,3-b]pyridine (L-750,667) and evaluated as potential dopamine D(4) receptor imaging agents by positron emission tomography (PET). Binding affinities of these ligands for the dopamine D(2), D(3), and D(4) receptor subtypes were measured in vitro. Most ligands showed high and selective binding for the D(4) receptor. Ligand 7 had high affinity for the D(4) receptor, whereas ligands 1, 2, and 6 showed high selectivity for the D(4) receptor. LogP values were calculated for the ligands in this series and ligand 6 had the lowest lipophilicity. (18)F-labeled ligand 7 demonstrated a uniform regional brain distribution and a rapid washout in mice, probably due to nonspecific binding. Based on their in vitro binding properties and calculated logP values, ligand 6 appears to have the most promise for dopamine D(4) receptor imaging.


Subject(s)
Fluorine/metabolism , Pyridines/chemical synthesis , Pyridines/metabolism , Receptors, Dopamine D2/metabolism , Animals , Drug Evaluation, Preclinical/methods , Fluorine/chemistry , Hydrogen/metabolism , Male , Mice , Mice, Inbred ICR , Protein Binding/physiology , Receptors, Dopamine D4
7.
Bioorg Med Chem ; 12(2): 371-85, 2004 Jan 15.
Article in English | MEDLINE | ID: mdl-14723956

ABSTRACT

We recently reported that N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl] thiourea (2) was a high affinity antagonist of the vanilloid receptor with a binding affinity of K(i)=63 nM and an antagonism of K(i)=53.9 nM in rat VR1 heterologously expressed in Chinese hamster ovary (CHO) cells (Mol. Pharmacol. 2002, 62, 947-956). In an effort to further improve binding affinity and antagonistic potency, we have modified the C-region of the lead 4-t-butylbenzyl group with diverse surrogates, such as araalkyl, alkyl, 4-alkynylbenzyl, indanyl, 3,3-diarylpropyl, 4-alkoxybenzyl, 4-substituted piperazine and piperidine. The lipophilic surrogates, arylalkyl and alkyl, conferred modest decreases in binding affinities and antagonistic potencies; the groups having heteroatoms resulted in dramatic decreases. Our findings indicate that 4-t-butylbenzyl is one of the most favorable groups for high receptor binding and potent antagonism to VR1 in this structural series.


Subject(s)
Receptors, Drug/antagonists & inhibitors , Thiourea/analogs & derivatives , Animals , Biochemistry/methods , CHO Cells , Capsaicin/pharmacology , Cricetinae , Drug Evaluation, Preclinical/methods , Rats , Receptors, Drug/metabolism , Structure-Activity Relationship
8.
Oncol Res ; 13(1): 37-45, 2002.
Article in English | MEDLINE | ID: mdl-12201673

ABSTRACT

Alpinia oxphylla Miquel, which belongs to the ginger family (Zingiberaceae), has been used in Oriental herbal medicine. Our recent studies have revealed that the methanolic extract of A. oxyphylla suppresses mouse skin tumor promotion and induces apoptosis in cultured human promyelocytic leukemia cells. In the present work, we have assessed effects of yakuchinone A and yakuchinone B, phenolic diarylheptanoids derived from A. oxyphylla, on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation and epidermal ornithine decarboxylase (ODC) activity as well as on skin tumor promotion in female ICR mice. Thus, topical application of 2 or 6 micromol of the diarylheptanoids prior to each topical dose of TPA significantly ameliorated 7,12-dimethylbenz[a]anthracene-initiated mouse skin tumor formation. In parallel with suppression of tumor promotion, topically applied yakuchinone A and B markedly inhibited TPA-induced epidermal ODC activity and ODC mRNA expression. In another experiment, yakuchinone A and B reduced production of tumor necrosis factor-alpha in TPA-stimulated mouse skin. Furthermore, both compounds inhibited the TPA-induced expression of cyclooxygenase-2 at both transcriptional and translational levels. These findings indicate that pungent diarylheptanoids from A. oxyphylla Miquel have an antitumor promotional activity that might be related to their anti-inflammatory properties.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/isolation & purification , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Guaiacol/analogs & derivatives , Phytotherapy , Skin Neoplasms/prevention & control , Skin/pathology , Zingiber officinale , Animals , Curcumin/therapeutic use , Diarylheptanoids/therapeutic use , Edema/prevention & control , Guaiacol/therapeutic use , Inflammation/drug therapy , Mice , Skin/drug effects , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL